Table 2.
Findings on Multimodal Imaging in Patients With cCSC and Secondary PCRD Manifestation
| Imaging | Features | No. of Eyes (%/SD) |
| OCT at first PCRD manifestation | SRF | |
| Subfoveal | 52 (63) | |
| Peripheral | 11 (13) | |
| No SRF | 20 (24) | |
| PCRD association with PD | ||
| Dome-shaped | 15 (18) | |
| Irregular flat | 30 (36) | |
| No PD association | 38 (46) | |
| PCRD location in posterior pole | ||
| Peripapillary region | 32 (39) | |
| Papillomacular region | 35 (30) | |
| Foveal | 15 (18) | |
| Other* | 11 (13) | |
| PCRD location in retinal layers† | ||
| ONL | 16 (19) | |
| INL, ONL | 61 (74) | |
| INL, OPL, ONL | 5 (6) | |
| GCL, INL, ONL | 1 (1) | |
| OCT at final visit | SRF | |
| Subfoveal | 9 (11) | |
| Peripheral | 6 (7) | |
| Complete resolution | 68 (82) | |
| Presence of PCRD | ||
| Complete resolution | 31 (37) | |
| Reduced | 17 (21) | |
| Increased | 5 (6) | |
| Unchanged | 30 (36) | |
| FA after PCRD manifestation | Fluorescein leakage | |
| Focal | 29 (35) | |
| Diffuse | 36 (43) | |
| No leakage | 18 (22) | |
| Leakage associated with PCRD | 50 (60) | |
| Area of RPE atrophy in DD | 7.1 (SD = 4) | |
| RPE atrophy associated with PCRD | 69 (83) |
*
Other PCRD locations without foveal involvement included: five eyes (6%) temporal and nasal to fovea, three eyes (4%) temporal to fovea, two eyes (2%) inferior to fovea, one eye (1%) in papillomacular region and temporal to fovea.
†
The cystoid changes were larger and more prominent in the ONL in 70 eyes (84%), in 9 eyes (11%) in the INL, and in four eyes (5%) cystoid changes were equally prominent in the INL and ONL.
DD, optic disc diameter; ETDRS, early treatment diabetic retinopathy study; GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; and PD, RPE detachment.